Table 3.
Response assessment according to RECIST 1.1 and mRECIST criteria
| Study | N | Criterion | CR | PR | SD | PD |
| Spira et al20 | 25 | RECIST1.1 | 1 | 0 | 18 | 6 |
| mRECIST | 1 | 11 | 9 | 4 | ||
| Edeline et al16 | 53 | RECIST1.1 | 0 | 1 | 42 | 10 |
| mRECIST | 2 | 10 | 30 | 11 | ||
| Moschouris et al22 | 21 | RECIST1.1 | 0 | 1 | 16 | 4 |
| mRECIST | 2 | 6 | 11 | 2 | ||
| Kawaoka et al21 | 49 | RECIST1.1 | 1 | 1 | 30 | 17 |
| mRECIST | 2 | 4 | 26 | 17 | ||
| Arizumi et al23 | 156 | RECIST1.1 | 3 | 12 | 71 | 70 |
| mRECIST | 6 | 30 | 55 | 65 | ||
| Bargellini et al24 | 22 | RECIST1.1 | 0 | 1 | 5 | 16 |
| mRECIST | 0 | 4 | 5 | 13 | ||
| Ronot et al14 | 64 | RECIST1.1 | 2 | 43 | 19 | |
| mRECIST | 18 | 29 | 17 | |||
| Salvaggio et al25 | 17 | RECIST1.1 | 0 | 2 | 10 | 5 |
| mRECIST | 0 | 3 | 10 | 4 | ||
| McNamara et al26 | 21 | RECIST1.1 | 0 | 2 | 19 | 0 |
| mRECIST | 1 | 6 | 14 | 0 | ||
| Takada et al15 | 175 | RECIST1.1 | 4 | 11 | 80 | 80 |
| mRECIST | 5 | 20 | 72 | 78 | ||
| Gavanier et al27 | 60 | RECIST1.1 | 0 | 2 | 28 | 30 |
| mRECIST | 0 | 4 | 27 | 29 | ||
| Ikeda et al28 | 42 | RECIST1.1 | 0 | 11 | 25 | 6 |
| mRECIST | 0 | 17 | 19 | 6 | ||
| Pelosof et al29 | 379 | RECIST1.1 | 0 | 25 | 354 | |
| mRECIST | 2 | 38 | 339 | |||
| Kaneko et al30 | 40 | RECIST1.1 | 1 | 9 | 21 | 9 |
| mRECIST | 3 | 12 | 9 | 4 | ||
| Kawamura et al31 | 51 | RECIST1.1 | 0 | 26 | 21 | 4 |
| mRECIST | 6 | 32 | 9 | 4 | ||
| Kuzuya et al32 | 10 | RECIST1.1 | 0 | 0 | 8 | 2 |
| mRECIST | 0 | 1 | 7 | 2 | ||
| Maruta et al33 | 131 | RECIST1.1 | 2 | 22 | 78 | 29 |
| mRECIST | 3 | 59 | 42 | 27 | ||
| Yamamichi et al34 | 22 | RECIST1.1 | 1 | 1 | 12 | 8 |
| mRECIST | 1 | 1 | 7 | 13 | ||
| Murakami et al19 | 27 | RECIST1.1 | 0 | 0 | 16 | 11 |
| mRECIST | 1 | 2 | 13 | 11 | ||
| He et al35 | 86 | RECIST1.1 | 0 | 8 | 54 | 24 |
| mRECIST | 0 | 14 | 48 | 24 | ||
| Nair et al36 | LEN: 478 | RECIST1.1 | 19 | 459 | ||
| mRECIST | 41 | 437 | ||||
| SOR: 476 | RECIST1.1 | 7 | 469 | |||
| mRECIST | 12 | 464 | ||||
| Salem et al37 | 158 | RECIST1.1 | 18 | 140 | ||
| mRECIST | 22 | 136 | ||||
| Yamashige et al38 | 11 | RECIST1.1 | 6 | 5 | ||
| mRECIST | 9 | 2 | ||||
CR, complete response; LEN, Lenvatinib; mRECIST, modified RECIST; PD, progressive disease; PR, partial response; RECIST 1.1, Response Evaluation Criteria in Solid Tumours version 1.1; SD, stable disease; SOR, Sorafenib.